Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04429542

Public ClinicalTrials.gov record NCT04429542. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 30, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors

Study identification

NCT ID: NCT04429542
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Bicara Therapeutics; Industry
Enrollment: 292 participants

Conditions and interventions

Conditions

Interventions

BCA101 Drug
Pembrolizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 31, 2020
Primary completion: Dec 30, 2026
Completion: May 31, 2027
Last update posted: Aug 14, 2025

2020 – 2027

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 13

Facility	City	State	ZIP	Site status
Moores Cancer Center UC San Diego Health	La Jolla	California	92093	Recruiting
Keck School of Medicine of USC	Los Angeles	California	90033	Recruiting
UCLA	Los Angeles	California	90095	Recruiting
University of California, Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
H. Lee Moffitt Cancer Center and Research Institute, Inc	Tampa	Florida	33612	Recruiting
Dana Farber/Partners Cancer Care Inc	Boston	Massachusetts	02115	Recruiting
Memorial Sloan Kettering	New York	New York	10017	Recruiting
Columbia University Herbert Irving Comprehensive Cancer Center	New York	New York	10032	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
Rhode Island Hospital	Providence	Rhode Island	02903	Recruiting
Medical University of South Carolina, Hollings Cancer Center	Charleston	South Carolina	29425	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04429542, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 14, 2025 · Synced Apr 30, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04429542 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →